Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®

Background: In acromegaly, expert surgery is curative in only about 60% of patients. Postoperative radiation therapy is associated with a high incidence of hypopituitarism and its effect on growth hormone (GH) production is slow, so that adjuvant medical treatment becomes of importance in the management of many patients.

Objective: To delineate the role of lanreotide in the treatment of acromegaly.

Methods: Search of Medline, Embase, and Web of Science databases for clinical studies of lanreotide in acromegaly.

Results: Treatment with lanreotide slow release and lanreotide Autogel® normalized GH and insulin-like growth factor-I (IGF-I) concentrations in about 50% of patients. The efficacy of 120 mg lanreotide Autogel® on GH and IGF-I levels was comparable with that of 20 mg octreotide LAR. There were no differences in improvement of cardiac function, decrease in pancreatic β-cell function, or occurrence of side effects, including cholelithiasis, between octreotide LAR and lanreotide Autogel®. When postoperative treatment with somatostatin analogs does not result in normalization of serum IGF-I and GH levels after noncurative surgery, pegvisomant alone or in combination with somatostatin analogs can control these levels in a substantial number of patients.

Keywords: acromegaly, lanreotide, somatostatin analog, growth hormone, pegvisomant

Introduction

Growth hormone (GH), a polypeptide consisting of 191 amino acids and which is secreted by the pituitary gland, has a multitude of effects. The most obvious effect is the stimulation of growth in prepubertal and pubertal children. In childhood, lack of this hormone leads to dwarfism and excessive secretion results in gigantism. Growth hormone has profound metabolic effects by stimulating protein anabolism and lipolysis. Other effects include stimulation of bone turnover, leading to a net increase in bone volume, muscle growth, insulin antagonism, renal sodium retention, and immuno modulation. Most of the effects of GH are indirectly mediated via insulin-like growth factor-I (IGF-I). IGF-I is a peptide synthesized and secreted as a result of GH-signaling, which acts locally in an autocrine or paracrine manner, or systematically as a hormone when secreted by the liver (Le Roith et al 2001). The liver secretes about 70% of the total circulating IGF-I in mice (Sjogren et al 1999).

Excessive secretion of GH leads to acromegaly, a disfiguring and debilitating condition causing severe co-morbidity and premature death (Wright et al 1970; Ezzat et al 1994; Melmed 2006; Ben-Shlomo and Melmed 2008).

The purpose of this review is to establish the role of lanreotide, particularly lanreotide Autogel®, in the management of acromegaly based on published data. It is appropriate, however, to outline first the clinical features of acromegaly and to discuss therapeutic approaches in its management.
Acromegaly is a rare disease, caused by a GH-secreting adenoma and in even more seldom instances (about 1%) due to excessive GHRH secretion, usually by a carcinoid tumor of the lung or gastrointestinal tract (Biermasz et al 2007). The incidence of acromegaly is about 3–4 per 1 million per year and the prevalence is 60–70 per 1 million, without geographical or sex differences (Alexander et al 1980 Bengtsson et al 1988; Ritchie et al 1990; Mestron et al 2004). Clinical features of acromegaly include acral enlargement, prognatism, jaw malocclusion, arthropathy, carpal tunnel syndrome, hyperhidrosis, sleep apnea, and visceromégalies (Colao et al 2004; Melmed 2006). Acromegaly is also associated with increased cardiovascular morbidity and mortality. Active disease leads to a specific form of cardiomyopathy which involves myocardium, conduction system, and heart valves. Clinical manifestations include arrhythmias, valvular regurgitation, concentric left ventricular hypertrophy, and left ventricular systolic and diastolic dysfunction (Clayton 2003; Colao et al 2004; Pereira et al 2004). The incidence of hypertension and of decreased glucose tolerance is also increased. This is also true for the incidence of colon polyps and colon carcinoma (Orme et al 1998; Renehan and Shalet 2002). It is controversial, however, whether the relative risk of cancer is increased in patients with acromegaly compared with that of the general population (Jenkins and Besser 2001; Melmed 2001; Looper and Ezzat 2008).

Local tumoral symptoms include chronic headache, visual field defects, and rarely cranial nerve palsies. Hypopituitarism is mostly associated with large tumors with a generally low incidence in patients with acromegaly varying from 3% to 10% (Greenman et al 1995). The increased standardized mortality rate (SMR) decreased from 3-fold in older series to 1.3-fold in series with predominantly primary transsphenoidal surgery (Swaeringen et al 1998; Holdaway et al 2004; Kauppinen et al 2005; Holdaway 2007; Dekkers et al 2008). Reported risk factors include diabetes mellitus, cardiomyopathy, sleep apnea, and cerebrovascular events and in some, but not all, studies also pituitary irradiation (Ayuk et al 2004; Biermasz et al 2004a; Kauppinen et al 2005). The decrease in mortality observed in acromegaly is likely to be due to the introduction of effective therapies such as transsphenoidal surgery in the 1970s and to postoperative radiotherapy, leading to normalization of GH and IGF-I concentrations in a substantial number of patients. The effective treatment of systemic co-morbidities also plays a role in the observed decrease in mortality. Only few patients using adjuvant somatostatin analogs are included in mortality series and it is of note that at present no mortality data exist for primary medical treatment including pegvisomant treatment. Most studies have suggested that a lower GH, for example below 2.5 μg/L, is associated with improved and even normal survival. In some but not all studies normal IGF-I was also associated with improved mortality (Ayuk et al 2004; Biermasz et al 2004a; Holdaway et al 2004; Kauppinen et al 2005). Discrepancies between studies may be explained by a single GH or IGF-I measurement being used in most studies, which is hardly representative for disease status in the entire follow-up period; by the unavailability of IGF-I in a substantial number of patients; and by GH and IGF-I assay differences. In addition, individual mortality studies consist of relatively small numbers of patients with large confidence intervals including 1.0, limiting statistical power.

In acromegaly detailed studies of spontaneous GH secretion have demonstrated increased pulsatility (increased pulse frequency), amplified burst mass, and increased basal secretion, associated with decreased regularity (Barkan et al 1989; Ho et al 1994; van den Berg et al 1994). Biochemical criteria of active disease and remission are the (mean) GH level, glucose-suppressed GH concentration, and the IGF-I level (Giustina et al 2000). GH assays differ in specificity, sensitivity, and GH standard, and therefore individual clinical endocrine laboratories should establish normal ranges of gender- and age-related GH and IGF-I values and ideally corrected for fat mass or a fat mass-derived parameter (Gullu et al 2004; Bidlingmaier and Strasburger 2007). Circulating IGF-I reflects GH secretion rate and serum concentrations of IGF-I are elevated in all patients with active disease (Melmed 2006). IGF-I concentrations decrease with advancing age. In addition, gender, sex hormone status, the use of oral estrogens, thyroxin, and body composition can all influence IGF-I concentrations (Clemmons 2007).

Treatment of acromegaly

As discussed above, epidemiological studies have clearly demonstrated that controlling GH and IGF-I secretion is the most significant determinant of restoring survival in patients with acromegaly. The main goal of treatment of acromegaly is therefore to achieve GH levels of less than 1 μg/L after a glucose load, to normalize age- and gender-matched IGF-I levels, to ablate or reduce tumor mass and prevent its recurrence, and to alleviate significant co-morbid conditions, especially cardiovascular, pulmonary, and metabolic disturbances (Melmed et al 2002). The currently available treatment modalities for acromegaly are selective transsphenoidal adenomectomy, radiotherapy, medical treatment, or combinations thereof.
Transsphenoidal surgery
This oldest treatment modality was developed a century ago by the Austrian neurosurgeon Schloffer (Schloffer 1907). It is generally performed via the transnasal, transsphenoidal route and is associated with low morbidity and mortality. In recent years most neurosurgeons have adopted the endoscope in lieu of the surgical microscope, which has obvious advantages for the patient and also leads to better visualization of the operating field. Other variants of surgical techniques are neuronavigating and real-time intraoperative MRI scanning, aimed at visualization of tiny tumor remnants after resection of the adenoma (Fahlbusch et al 2005; Thomale et al 2005). GH secretion pattern is restored when the adenoma is completely removed (van den Berg et al 1998). Surgical cure is highest in patients with a microadenoma (diameter less than 10 mm) varying from 80% to more than 90% in the hands of experienced neurosurgeons. However, complete tumor removal becomes more difficult with increasing size of the tumor and expansion into the neighboring delicate structures, and the cure rate of large macroadenoma drops to only 20%–40% of cases (Freda et al 1998; Biermasz et al 2000a; Kaldas et al 2001; Kreutzer et al 2001; Shimon et al 2001; Beauregard et al 2003; De et al 2003; Nomikos et al 2005; Lüdecke and Abe 2006). The obvious advantage of successful surgery is the rapid normalization of GH secretion and decrease in IGF-I levels, while the complication of (partial) hypopituitarism is generally below 10% (Nomikos et al 2005; Lüdecke and Abe 2006). Second surgical procedures are generally safe but less successful than primary surgery (Long et al 1996). The experience of the neurosurgeon is critical for a high cure rate (Ahmed et al 1999; Bates et al 2008).

Radiotherapy
Conventional radiotherapy is administered by a linear accelerator (4–8 MeV) with a total dose of 40–45 Gy, fractionated in at least 20 sessions. A rotational field, 2 opposing fields, or a 3-field technique are used. A mean GH decrease of about 50% is observed in the first 2 years after irradiation and after 5 years a 75% decline is reported (Biermasz et al 2000b; Wass et al 2003). Whether the GH level normalizes post irradiation mainly depends on pre-irradiation serum GH concentration and the time interval between radiotherapy and the measurement of GH and IGF-I levels. Post-irradiation remission rates are, however, largely affected by the extent of surgical debulking prior to radiotherapy. Other than the slow onset of GH control another drawback is the increasing incidence of hypopituitarism varying from 50%–85% after a follow-up of 10 years or longer (Minniti et al 2005; Biermasz et al 2006).

Barkan and colleagues were the first to question the efficacy of radiotherapy in normalizing serum IGF-I concentrations, with many studies addressing the effects of conventional pituitary irradiation on IGF-I and strict GH criteria being reported thereafter (Barkan et al 1997). A few reports supported an apparent lack of efficacy of pituitary irradiation (Thalassinos et al 1998; Cozzi et al 2001), whereas others reported normalization of IGF-I in 44%–79% of patients after 5–15 years of follow-up (Ciccarelli et al 1993; Barrande et al 2000; Powell et al 2000; Epaminonda et al 2001; Minniti et al 2005).

Another radiation technique is radiosurgery, which is the precise, stereotactic delivery of a single high radiation dose to a defined target with a steep dose gradient at the tumor margin (Mahmoud Ahmed et al 2001; Castinetti et al 2005; Roberts et al 2007). This form of radiotherapy is performed using a gamma knife with up to 200 60Co sources, a Linac-based system, or proton beams (Marcus and Plowman 2000; Brada et al 2004; Sheehan et al 2005). The perceived advantage of this form of irradiation is that only one session is required. There is otherwise no convincing evidence as yet that radiosurgery is superior to conventional irradiation in terms of GH control, time needed to reach clinically acceptable GH levels, and incidence of hypopituitarism (Landolt et al 1998; Attanasio et al 2003a; Biermasz et al 2006).

Disadvantages of pituitary irradiation other than the development of hypopituitarism include decreased quality of life (QoL), the development of secondary tumors, cerebrovascular disease, and increased mortality. In one cross-sectional study, decreased health-related QoL was described in acromegalic patients in long-term remission (Biermasz et al 2004b). These data were confirmed by another QoL analysis of treated acromegalic patients (Rowles et al 2005). A significant predictor of poor QoL was radiotherapy, but the pathophysiologic mechanism remains unclear. Increased mortality due to cerebrovascular disease was observed in two of the studies (Ayuk et al 2004; Kauppinen et al 2005) but not in the other three (Bates et al 1993; Ahmed et al 1999; Biermasz et al 2004a). The effect of radiotherapy on mortality is thus as yet to be established. The likelihood of secondary tumor formation after pituitary irradiation is very low (Brada et al 1992).

Medical treatment
The three most important drugs used for medical treatment of acromegaly are dopamine agonists, somatostatin analogs, and GH-receptor modulating chemicals.
Dopamine agonists
Bromocriptine, a dopamine agonist, effectively reduces GH secretion in only a minority of GH-secreting adenoma (Jaffe and Barkan 1992). Cabergoline, a more potent dopamine agonist with prolonged duration of action, was reported to normalize GH in 35% and IGF-I in 44% of 46 patients with a purely GH-secreting adenoma when given at a dose of 1–1.75 mg/week (Abs et al 1998). The efficacy of cabergoline was somewhat better in tumors co-secreting prolactin. Quinagolide, another dopamine agonist, was reported to normalize IGF-I in 28% of patients (Freda 2003). Most endocrinologists use long-acting dopamine agonists as adjunct therapy in patients who fail to normalize GH secretion with octreotide monotherapy. The combination therapy normalizes serum IGF-I concentrations in 30%–40% of patients, irrespective of the prolactin concentration (Cozzi et al 2004).

Somatostatin analogs
Somatostatin was isolated in 1973 from the hypothalamus and subsequently synthesized (Brazeau et al 1973). The hormone is processed from a large pre-prohormone into 2 cyclic peptides, consisting of 14 or 28 amino acids. The short form, SS14, is predominantly present in the brain, whereas SS28 is widely distributed in peripheral organs. Somatostatin acts as neuromodulator and neurotransmitter in the brain and as a neurohormone in the regulation of GH and thyroid-stimulating hormone secretion. In addition, somatostatin inhibits tumoral adrenocorticotropic hormone secretion in Cushing’s disease (van der Hoek et al 2004). Somatostatin acts as neurotransmitter in the extensive myo-enteric plexus, and as hormone in a paracrine and autocrine fashion. Via specific receptors, somatostatin exerts many inhibitory effects on gut and pancreatic hormones, including gastrin, insulin, glucagon, vasoactive intestinal peptide, motilin, and gastric inhibitory polypeptide. Other effects of somatostatin include inhibition of gastric emptying, pancreatic enzymes and bicarbonate secretion, gastrointestinal blood flow and bile flow (Brazeau et al 1973; Reichlin 1983; Patel 1999). Somatostatin acts via a G-protein-coupled receptor, of which 5 subtypes have been cloned and characterized (Lamberts et al 1996).

After binding of somatostatin to its receptor, the activities of adenyl cyclase and of calcium channels are inhibited, whereas phosphotyrosine phosphatase activity and mitogen-activated protein kinases activity are stimulated. The first two processes are involved in the inhibition of secretory processes, and the latter two may play a role in cell proliferation, eg, activation of the SST3 receptor may induce apoptosis (Danilla et al 2001; Bevan 2005). Analogs of somatostatin differ in binding properties to different receptor subtypes (Lamberts et al 1996). Many benign and malignant tumors express one or more somatostatin receptors. Receptor distribution and density and homogeneity of receptor expression within the tumor determine whether a particular analog can be effectively used therapeutically (Krantic et al 2004; Olias et al 2004).

GH-secreting pituitary adenomas express predominantly SST2 and SST5 receptors. The current clinically used analogs, octreotide and lanreotide, inhibit GH secretion via the somatostatin receptor subtypes 2 and 5 (Hofland and Lamberts 2003). The plasma half-life of these analogs is about 20 times longer than that of native somatostatin, which is less than 3 minutes (Lamberts et al 1996). Although the most important effect of somatostatin analogs is the inhibition of GH secretion by the adenoma leading to a subsequent decrease in circulating liver-derived IGF-I, part of the peripheral effects of these analogs is caused by the direct inhibition of IGF-I gene transcription after binding to the somatostatin receptor (Serri et al 1992; Murray et al 2004). The magnitude of this latter effect in various organs is not exactly known.

GH receptor antagonists
Pegvisomant is an engineered GH analog that antagonizes GH at the receptor site, and thus prevents endogenous GH activation of its receptor and subsequent downstream signaling. In short-term studies, the lowest dose (10 mg/day) normalized IGF-I in 38% of the patients and 20 mg normalized IGF-I in 82% of patients (Trainer et al 2000; van der Lely et al 2001). In a minority of patients (2 out of 112 and 7 out of 229 patients, respectively) adenoma size increased during a relatively short treatment period (van der Lely et al 2001; Schreiber et al 2007). Careful documentation of tumor size before starting pegvisomant treatment is therefore compulsory and long-term monitoring is advisable. A small number of patients (2 out of 167 cases) developed abnormalities in liver function tests, necessitating withdrawal of the drug, although increased liver enzyme levels, ie, more than 3 times the upper level of normal, was observed in 5.5% of 229 patients, normalizing spontaneously in 3.1%
on continuing treatment (van der Lely et al 2001; Schreiber et al 2007). About 40% of patients develop minor abnor-
amalities in liver function tests on combined treatment with
somatostatin analogs, which do not requiring stopping of
the drug and which usually resolve spontaneously (Feenstra
et al 2005).

Pharmokinetics of lanreotide
The first pharmaceutical available form of lanreotide (BIM
23014) was relatively short-acting, requiring multiple dosing,
3 times a day, or subcutaneous infusion. This was nevertheless
a major advance in the treatment of many patients who
had already undergone unsuccessful surgery and pituitary irradiation and for whom there were no other treatment options (Figure 1). In healthy subjects, maximal serum concentrations of lanreotide were reached after 30 min and the serum half-life was 90 min, 30 times greater than that of
native somatostatin (Kuhn et al 1994; Antonijoan et al 2004;
Table 1). Subsequently, a long-acting form of lanreotide was
developed by incorporating the drug into polyactide – poly-
glycolide microspheres, so that the half-life was considerably
prolonged, and the injection interval could be extended to
7–14 days (Heron et al 1993). The lanreotide release pattern
from the long-acting form is biphasic, i.e., an early release
during 2 days from the drug adsorbed onto the surface of the
microspheres, followed by sustained release for about 1 week,
starting at day 4, as a result of enzymatic breakdown of the
microspheres, followed again by an exponential decrease in
drug release. It was subsequently discovered that lanreotide
had the unique property of self aggregation under favorable
conditions, leading to a stable structure of highly organized
nanotubules (Valery et al 2003, 2008). This formulation of
the drug was named lanreotide Autogel® and has a long half-
ilfe after subcutaneous injection determined by pseudo-first
order kinetics. Maximal serum concentrations are reached
after 1–2 days (see Table 1) in healthy subjects and the
serum half-life amounts to 25.5 days (Antonijoan et al 2004;
Astruc et al 2005). In acromegalic patients maximal values
are reached after 3.8–7.7 days under steady state conditions,
depending on the dose administered (Table 2). Simulated
steady state pharmacokinetic profiles of long-acting octreoi-
tide and lanreotide Autogel® differ significantly (Astruc et al
2005; Bronstein et al 2005). During long-acting octreotide
treatment, serum concentrations of the drug are more or
less stable, whereas the characteristic first-order kinetics of
lanreotide Autogel® is superimposed on levels just before the
next administration (see Figure 2; Astruc et al 2005). The
pharmacokinetic differences therefore indicate that octreotide
LAR can be better tailored to therapeutic levels, whereas
serum levels of lanreotide must be (too) high for part of the
interval between injections in order to be effective in the
period before the next administration. The possible clinical
consequence(s) of these different pharmacokinetic profiles
can be resolved only in long-term studies in which lanreotide
Autogel® is compared with octreotide or drugs with a similar
pharmacokinetic profile.

Efficacy of lanreotide
The first studies with lanreotide were performed using
lanreotide Slow Release (lanreotide SR). The drug was
first available in vials containing 30 mg, to be injected at
2-weekly intervals. The interval was shortened, however,
to 7–10 days when GH was insufficiently suppressed. The
drug later also became available in vials containing 60 mg
of lanreotide so that the injection interval could be extended
to 4 weeks, similar to that of the long established octreotide
LAR. Studies using lanreotide SR 30 mg and lanreotide
SR 60 mg are summarized in Table 3. Most patients had
undergone pituitary surgery and many were irradiated, either
as primary treatment (a minority) or as adjuvant treatment
after noncurative surgery. In addition, in almost all studies
patients had been treated with octreotide. Normal mean GH
concentration, as defined by the authors (generally below

![Figure 1](image-url)
2.5 μg/L) was achieved in 23%–93% of the cases treated with lanreotide SR 30 mg, and in 25%–65% of the cases treated with lanreotide 60 mg. Normal values of IGF-I were obtained in 23%–68% of patients on lanreotide SR 30 mg, and 35%–62% of these on lanreotide SR 60 mg. The weighted means of normalization of GH and of IGF-I were 54% and 49%, respectively, during treatment with 30 mg lanreotide, whereas during treatment with lanreotide SR 60 mg these values were 60% and 58%.

Comparative studies of efficacy between octreotide and lanreotide are summarized in Table 4. Short-acting octreotide, mostly given 3 times a day, had a similar GH-suppressive effect as lanreotide SR. Normal GH was obtained in 52% and 49% of a total of 218 patients, but normalized IGF-I was more frequently found in patients treated with lanreotide SR 30 mg/10–14 days, ie, 49% versus 64%. The efficacy of octreotide LAR was slightly higher than that of lanreotide SR: normalized GH and IGF-I were obtained in 64% and 62% of 155 patients treated with octreotide LAR versus 52% and 50%, respectively, in the same patients during treatment with lanreotide SR. A limitation of all these studies, with one exception, is that they were not randomized. The overall better efficacy of octreotide LAR compared with lanreotide SR agrees with findings from a recent meta-analysis (Freda et al 2005).

Lanreotide Autogel® was introduced about 8 years ago, and the first report in the English literature was published in 2002. Clinical efficacy studies are summarized in Table 5. Most of the patients who took part in these studies had undergone pituitary surgery, often with adjuvant irradiation, and almost all patients were on octreotide or lanreotide SR treatment, while a minority also used dopaminergic drugs. The results of these studies should therefore be considered critically, as a selection bias cannot be excluded. Normal GH, defined as a concentration below 2.5 μg/L in fasting single blood samples or as the mean of serial samples was observed in 38%–80% of cases and normal age-related IGF-I was recorded in 39%–80% of patients on lanreotide Autogel®. In these studies the weighted mean for GH normalization was 58% and for IGF-I 48% in a population of 370 patients. The results mentioned above refer to measurements at the end of the study when dose titration of lanreotide Autogel® was fully effective. Indeed, most of the patients ended receiving the highest dose of 120 mg. These results do not differ from

---

### Table 1: Pharmacokinetic analysis of a single subcutaneous dose of short-acting lanreotide and lanreotide Autogel® in healthy subjects

| Dose | Short-acting lanreotide* | lanreotide Autogel® |
|------|-------------------------|---------------------|
|      | 7 μg/kg                 | 60 mg               |
| Cmax | 7.98 ng/mL              | 5.71 ng/mL          |
| Tmax | 0.43 h                  | 0.38 day            |
| Half-life | 1.74 h | 22 days |
| AUC  | 16.51 ng/mL·h           | 79.48 ng/mL·day    |
| MRT  | 1.95 h                  | 31.97 days          |

| Dose | lanreotide Autogel® |
|------|---------------------|
|      | 90 mg               |
| Cmax | 6.7 ng/mL           |
| Tmax | 1.1 day             |
| Half-life | 1.1 day |
| AUC  | 116 ng/mL·day      |
| MRT  | 1.95 h              |

*Antonijoan et al (2004); Astruc et al (2005).

**Abbreviations:** AUC, area under the curve; MRT, mean residence time.

---

### Table 2: Pharmacokinetics of lanreotide Autogel® during steady state conditions in patients with acromegaly

| Dose | 60 mg | 90 mg | 120 mg |
|------|-------|-------|--------|
| Tmax (days) | 85     | 84    | 85     |
| Cmax (ng/mL) | 2.46   | 3.04  | 4.52   |
| Cmin (ng/mL) | 1.82   | 2.51  | 3.76   |
| Cmax (ng/mL) | 3.82   | 5.69  | 7.69   |
| AUC (ng/mL·day) | 68.8   | 85.1  | 127    |

From data of Bronstein et al (2005).

**Abbreviation:** AUC, area under the curve.

---

![Figure 2](image-url)
### Table 3  Efficacy of lanreotide slow release (SR) on serum GH and IGF-I concentrations in acromegaly

| Reference | Patient no | Previous surgery and/or radiotherapy | Previous medication (number) | Used medication | Duration (months) | GH normal | IGF normal | Comments |
|-----------|------------|--------------------------------------|-----------------------------|----------------|-----------------|-----------|------------|----------|
| Heron 1993 | 14         | 14                                   | none                        | Lanreotide SR 30 mg/14 d | 6               | 93%       | 64%        | IGF-I < 350 ng/mL, GH < 5 μg/L |
| Johnson 1994 | 8          | 5                                    | none                        | Lanreotide SR 30 mg/14 d | 6               | 50%       | 38%        | No SDS for IGF-I, GH < 10 mU/L |
| Marek 1994  | 13         | 13                                   | none                        | Lanreotide SR 30 mg/14 d | 9–19            | 23        | 23%        | IGF-I < 270 μg/L, GH < 5 μg/L |
| al-Maskari 1996 | 10        | 10                                   | octreotide (7)              | Lanreotide SR 30 mg/10–14 d | 6               | 60%       | 50%        | No SDS for IGF-I, GH < 5 mU/L |
| Caron 1997  | 22         | 7                                    | octreotide (21)             | Lanreotide SR 30 mg/10–14 d | 6–36            | 27.2%     | 64%        | IGF < 300 ng/mL for all subjects |
| Giusti 1997 | 57         |                                      | octreotide SR (37)          | Lanreotide SR 30 mg/10–14 d | 6               | 54%       | 35%        | Normal IGF < mean + 3SD; normal GH < 5 μg/L |
| Morange 1994 | 19         | 13                                   | octreotide (14)             | Lanreotide SR 30 mg/10–14 d | 6               | 68%       | 68%        | IGF-I not age-adjusted |
| Suliman 1999 | 30         | 21                                   | octreotide (7)              | Lanreotide SR 30 mg/10–14 d | 12              | 78%       | 35%        | IGF-I not age-adjusted |
| Colao 1999  | 45         | 25                                   | octreotide (45)             | Lanreotide SR 30 mg/10–14 d | 6               | 58%       | 58%        | Age-adjusted IGF-I |
| Baldelli 2000 | 118     | 95                                   | octreotide (95)             | Lanreotide SR 30 mg/10–14 d | 24              | 61%       | 52%        | Age-adjusted IGF-I |
| Verhelst 2000 | 66        | 37                                   | octreotide (55)             | Lanreotide SR 30 mg/7–14 d | 12              | 45%       | 44%        | Age-adjusted IGF-I |
| Chanson 2000b | 58        | 58                                   | octreotide (38)             | Lanreotide SR 30 mg/10–4 d | 12              | 41%       | 41%        | Selected from 116 patients |
| Cannavo 2000 | 18         | 10                                   | octreotide (16)             | Lanreotide SR 30 mg/10–30 d | 6               | 50%       | 44%        | IGF-I not age-adjusted |
| Cozzi 2000  | 10         | none                                 | none                        | Lanreotide 60 mg/28–21 d | 6               | 25%       | 62%        | IGF-I not age-adjusted |
| Ambrosio 2002 | 20        | 13                                   | lanreotide SR 30 mg/ octreotide (15) | Lanreotide 60 mg/28–21 d | 8               | 65%       | 35%        | Age-adjusted IGF-I |
| Attanasio 2003b | 92        | 62                                   | octreotide or lanreotide SR (40) | Lanreotide 60 mg/28/21/14 d | 24              | 63%       | 65%        | Age-adjusted IGF-I |
### Table 4 Comparison of efficacy of octreotide versus lanreotide SR in acromegaly

| Reference       | Number of patients | Octreotide | Lanreotide | Octreotide dose | Lanreotide dose |
|-----------------|--------------------|------------|------------|-----------------|----------------|
| Morange 1994    | 19                 | 16/19      | 16/19      | 0.15–0.6 mg/d   | 8/19           |
| Caron 1997      | 21                 | 12/21      | 17/21      | 0.1–0.6 mg/d    | 6/22           |
| Colao 1999      | 45                 | 23/45      | 23/45      | 0.15–0.6 mg/d   | 26/45          |
| Razzore 1999    | 38                 | 18/38      | 19/38      | 0.15–0.6 mg/d   | 9/38           |
| Baldelli 2000   | 95                 | 45/95      | 32/95      | 0.1–0.6 mg/d    | 58/95          |
| Kendall-Taylor 2004 | 5               | 4/5        | 5/5        | LAR 20–30 mg/4 w | 4/5           |
| Turner 1999     | 10                 | 8/10       | 7/10       | LAR 20–30 mg/4 w | 7/9           |
| Cozzi 1999      | 12                 | 4/10       | 5/10       | LAR 10–30 mg/4 w | 1/10          |
| Chanson 2000a   | 125                | 68%        | 65%        | LAR 20–30 mg/4 w | 54%           |
| Caron 2002§     | 20                 | 50%        | 50%        | LAR 10–30 mg/4 w | 58%           |

#### Abbreviations:
- ITT: intention-to-treat
- PPP: patients per protocol
- PS: pituitary surgery
- RT: radiotherapy
- MT: previous medical treatment
- LSR: lanreotide slow release
- oLAR: octreotide LAR

### Table 5 Clinical studies with lanreotide Autogel® in acromegaly

| Reference        | Study design         | Patient no. | Previous treatment | Dosing lanreotide Autogel | Duration (months) | Normal GH (< 2.5 μg/L) | Normal age-adjusted IGF-I | Previous medication |
|------------------|----------------------|-------------|--------------------|---------------------------|------------------|------------------------|--------------------------|---------------------|
| Caron 2002       | open label MC        | 144/107     | 81/49/107          | 60/90/120 mg              | 3                | 56%                    | 48%                      | LSR 30 mg/7–14 d     |
| Alexopoulos 2004 | open label MC        | 25/25       | 13/5/25            | 60/90/120 mg              | 6                | 48%                    | 52%                      | oLAR 20–40 mg/4 w    |
| Ashwell 2004     | open label MC        | 12/10       | 7/5/10             | 60/90/120 mg              | 7                | 80%                    | 80%                      | oLAR 20 mg/4 w       |
| Caron 2004       | extension study      | 131/130     | 99/57/131          | 60/90/120 mg              | 12               | 68%                    | 50%                      | Lan-Autogel          |
| Gut 2005         | open label           | 11          | 10/0/10            | 60/90/120 mg              | 16               | ?                      | 54%                      | LSR 30 mg/7–14 d     |
| Caron 2006       | extension study      | 14/14       | 9/5/14             | 60/90/120 mg              | 36               | 77%                    | 54%                      | LSR 30 mg/10–14 d    |
| Lucas 2006       | open label MC        | 99/93       | 76/53/99           | 120 mg/4–8 w              | 3                | 54%                    | 55%                      | LSR 30 mg/7–14 d     |
| Ronchi 2007      | open label MC        | 23/21       | 1/0/23             | 60/90/120 mg              | 9                | 56%                    | 39%                      | oLAR 10–30 mg/4 w    |
| Andries 2008     | randomized cross-over| 12/10       | 7/3/11             | Fixed dose 60/90/120 mg   | 12               | 42%                    | 50%                      | oLAR 10–30 mg/4 w    |
| Chanson 2008     | open label MC        | 63/57       | 37/12/49           | Fixed phase and dose titration | 12      | 38%                    | 43%                      | oLAR, lanreotide SR, lanreotide Autogel, washout |

#### Notes:
1. normal GH concentration < 0.38 μg/L.

#### Abbreviations:
- ITT: intention-to-treat
- PPP: patients per protocol
- PS: pituitary surgery
- RT: radiotherapy
- MT: previous medical treatment
- LSR: lanreotide slow release
- oLAR: octreotide LAR
- MC: multicenter
data obtained in patients on lanreotide SR (see above). Part of these studies compared the efficacy of octreotide LAR and lanreotide Autogel®. A drawback of these studies is that with the exception of one study none were randomized (Andries et al 2008). An open-label, uncontrolled, single-group assignment study on the effects of lanreotide Autogel® in 27 previously untreated patients with acromegaly was recently completed (ClinicalTrials.gov NCT00627796). Although the study is rather small it will contribute further data on IGF-I control and tumor reduction.

In a 3-month study in 107 patients, the normalization rate for GH was 48% during lanreotide SR and 56% during lanreotide Autogel® therapy, whereas a normal IGF-I was obtained in respectively 45% and 48% of cases (Caron et al 2002). In an extension phase of this study to 12 months, normalized GH frequency increased from 49% to 68% in 130 patients; these figures were 44% and 50% for IGF-I (Caron et al 2004). Fourteen patients of these studies were treated for 3 years with lanreotide Autogel®. In these patients the frequency of normal GH increased from 36% to 77% and that for IGF-I from 36% to 54% (Caron et al 2006). Finally, the Spanish multicenter study extended the Autogel® injection interval to 8 weeks in patients who were controlled by 2-weekly injections with lanreotide SR. The overall GH control increased from 46% to 54% (Lucas et al 2006). The studies comparing the efficacy between octreotide LAR and lanreotide are shown in Table 6. Only the small study by Andries was properly designed, and showed equal efficacies of both drugs in terms of normalization of GH. Nevertheless, this study demonstrated a better GH-suppressive effect of octreotide on absolute GH concentrations than lanreotide. In contrast, the suppressive effect on IGF-I was similar. There was no difference in GH suppressive effect in a small study in 7 patients in whom the 24 h GH secretion was precisely measured with a 10 min blood sampling protocol. (Van Thiel et al 2004). From the data presented above and despite limitations in design, it would appear that lanreotide Autogel® and octreotide LAR are equipotent in normalizing GH and IGF-I concentrations. Although patients require generally the highest lanreotide dose, most patients on octreotide LAR had safe GH and normal IGF-I levels on the 20 mg dose. For the practicing endocrinologist the message is that patients on octreotide LAR 20–30 mg need 120 mg lanreotide Autogel® and somatostatin-sensitive patients on octreotide LAR 10 mg require mostly 90 mg of the Autogel® formulation. Lanreotide Autogel® is registered under the trade name Somatuline Autogel® in the majority of countries, as Somatuline Depot Injection® in the US, and as Ipstyl Autogel® in a few European countries.

### Side effects

The most frequent side effects of lanreotide are diarrhea, abdominal pain, and nausea. These symptoms start mostly shortly after an injection, decrease subsequently, and tend to decrease in severity on continuing treatment. Table 7 lists the side effects mentioned in the clinical studies with the 2 long-acting formulations of lanreotide. For the SR formulation the gastrointestinal side effects were observed in 48% of the patients and for the Autogel® formulation in 52%. The most serious complication of somatostatin analogs is cholelithiasis. The prevalence of somatostatin analog-induced gallstones varies geographically and may be influenced by dietary, environmental, and racial factors. The formation of gallstones involves the inhibition of gallbladder emptying and intestinal motility, inhibition of the secretion of prokinetic peptides, including cholecystokinin, and increased intestinal and biliary production of deoxycholic acid, all of which promote the nucleation of cholesterol crystals and their aggregation into stones (Dowling et al 1992). We analyzed the occurrence of new cholelithiasis in patients who were already on somatostatin analog treatment, a condition thus not quite comparable to drug-naïve patients in terms of risk of developing gallstones. The incidence of new gallstones was 6% for lanreotide SR and 8.7% for lanreotide Autogel®. These figures are smaller than generally cited in literature,

| Reference   | Duration (months) | Patient no ITT/PPP | Octreotide LAR dose | Lanreotide Autogel dose | Normal GH oLAR | Normal GH lanreotide Autogel | Normal IGF-I oLAR | Normal IGF-I lanreotide Autogel |
|-------------|------------------|-------------------|---------------------|------------------------|----------------|-----------------------------|------------------|--------------------------------|
| Alexopoulos | 6                | 25/25             | 20–40 mg/4 w        | 60/90/120 mg           | 64%            | 48%                         | 52%              | 52%                            |
| Ronchi 2007 | 9                | 23/21             | 10–30 mg/4 w        | 60/90/120 mg           | 40%            | 56%                         | 35%              | 39%                            |
| Andries 2008| 12               | 12/10             | 10–30 mg/4 w Fixed dose 60/90/120 mg | 50% | 50% | 50% | 60% |

*normal GH concentration <0.38 μg/L.

Abbreviations: ITT, intention-to-treat; PPP, patients per protocol; oLAR, octreotide LAR.
but many patients had cholelithiasis caused by previous treatment.

Other side effects were local pain after injection and rarely (less than 1%) the development of nodules at the injection site. However, local infiltration signs did not decrease the efficacy of the drug. Other uncommon side effects included sinus bradycardia, asthenia, headache, pruritus, decreased libido, increased serum bilirubin, fatigue, constipation, and hair loss.

**Influence of lanreotide Autogel® on clinical manifestations**

Some studies have investigated specific aspects of lanreotide action in acromegaly. These include detailed studies on glucose and insulin metabolism, effects on cardiac function, tumor growth, quality of life, and predictors of clinical response. These reports are briefly summarized below.

**Insulin and glucose homeostasis**

GH is important in regulating glucose tolerance and insulin sensitivity. GH counteracts the effects of insulin by inhibiting the phosphorylation of the insulin receptor. Moreover, GH also inhibits the phosphorylation of one of the proximate molecules of the insulin signaling cascade, insulin receptor substrate-1 in response to insulin (Kuhn et al 1992). In acromegaly, several studies have shown that increased GH induces insulin resistance (Kasayama et al 2000). However, GH also potentiates insulin release which is reflected in the high prevalence of high insulin levels both at rest and after glucose challenge (Cerasi and Luft 1964). Indeed, many untreated patients exhibit decreased glucose tolerance and more detailed studies have shown reduced insulin-stimulated glucose disposal in muscle and impaired non-oxidative glucose metabolism (Sonksen et al 1967; Wass et al 1980; Hansen et al 1986; Foss et al 1991; Koop et al 1994). Effects of somatostatin analogs on glucose homeostasis are the resultant of delayed intestinal absorption of carbohydrates, inhibition of insulin release and increased insulin sensitivity via diminished GH secretion. Results from studies with lanreotide do not differ essentially from earlier data obtained with octreotide. The acute effects of subcutaneously infused lanreotide were studied in healthy subjects. Oral glucose tolerance worsened during the first day of administration, but was restored on day 7 while drug administration continued (Kuhn et al 1992). In a study in 27 patients the homeostasis...
model assessment (HOMA) index improved, but not the quantitative insulin check index (QUICKI) index (Ronchi et al 2003). In a cross-sectional study with 51 acromegalic patients of whom 18 were on lanreotide Autogel® the pancreatic β-cell function deteriorated but insulin resistance remained unchanged (Steffi n et al 2006). The most precise study used the euglycemic hyperinsulinenic clamp. Twenty-four patients were studied at baseline and after 6 months treatment with either octreotide LAR or with lanreotide SR. Hemoglobin A1c (HbA1c) increased significantly. In patients with a normal glucose tolerance at baseline the glucose concentration at 120 min increased, together with decreased and delayed insulin response. Insulin sensitivity increased in all 12 clamped patients. The investigators could not demonstrate differences between octreotide and lanreotide, ie, the effects on GH, IGF-I, and insulin were all similar (Baldelli et al 2003). The effects of other pharmacologic therapies currently used for the treatment of acromegaly on glucose metabolism and insulin resistance were recently reviewed (Pereira et al 2005). In most studies, not specifically focused on insulin and insulin resistance were recently reviewed (Pereira et al 2004). In addition, our group documented the increased prevalence of regurgitant valvular heart disease in acromegaly (Pereira et al 2004). In most studies, not specifically focused on insulin and glucose metabolism, fasting glucose concentrations and/or HbA1c levels did not change significantly when the GH-suppressive medication was changed to lanreotide or when the period of lanreotide administration was compared with the period without GH-suppressive medication.

Cardiac effects
Acromegaly is associated with increased cardiac morbidity and mortality. Recognized cardiac manifestations include chronic cardiac failure due to systolic dysfunction (cardiomyopathy) or isolated diastolic dysfunction (Colao et al 2004; Pereira et al 2004). In addition, our group documented the increased prevalence of regurgitant valvular heart disease in acromegaly (Pereira et al 2004). An important question is whether effective GH-suppressive medication can improve cardiac function. One of the first studies reported on 13 patients treated with lanreotide. In this study there was a parallel decrease in GH and IGF-I and in left ventricular mass index; these data were confirmed in another study (Baldelli et al 1999; Hradec et al 1999). Octreotide was used in most studies on cardiac function, because this drug was the earliest available for clinical studies (Maison et al 2007). These studies indicate that effective GH-suppressive medication improves morphological and functional hemodynamic parameters, although medical therapy does not normalize all parameters. These observations concur with results of another study, which compared outcome in long-term surgically cured patients with medically controlled patients and which showed better results in the first group (van Thiel et al 2005), suggesting that GH-suppressive therapy in its present form is unable to fully correct cardiac dysfunction. The impact of this finding on long-term mortality in acromegaly is unknown.

Tumor growth
The anti-tumoral effects of somatostatin analogs are linked to the activation of the subtype receptors SSTR1, SSTR2, SSTR4, and SSTR5, which all induce cell cycle arrest. Apoptosis is associated with SSTR3 and possibly also with SSTR2 signaling (Danilla et al 2001; Bevan 2005). GH secreting adenomas express different somatostatin receptors, as shown for example by a recent study in which 77% expressed SSTR2, 69% SSTR1 and SSTR3, and 60% SSTR5. In the same study, lanreotide inhibited cell proliferation in vitro in 10 out of 13 adenomas (Florio et al 2003). Lanreotide also stimulates apoptosis as was found in surgically removed GH secreting adenomas to 8.7 ± 2.6% in tumors compared with less than 3.5% in controls (Wasco et al 2003). The clinical response in terms of GH control and tumor size reduction correlates with the expression of somatostatin receptor subtype 2a (Fougner et al 2008; Taboada et al 2008) Preoperative treatment with lanreotide SR for 1–3 months in 104 acromegalic patients led to tumor size reduction in 66%, with a mean decrease of 152 mm³. A decrease in adenoma size of more than 20% was found in 29% of the patients (Lucas et al 2003). Other studies in which the decrease in adenoma size could be evaluated are listed in Table 7. In the meta-analysis of 14 clinical studies using somatostatin analogs as primary treatment, 36.6% of the patients exhibited a significant reduction in tumor size, with a weighted mean of 19.4% (Melmed et al 2005). Factors (not necessarily predictors) associated with tumor shrinkage after primary therapy with somatostatin analogs were post-treatment IGF-I, the age of the patient and the percentage GH decrease (Colao et al 2006), and essentially confirming previously reported findings (Lucas et al 2003). In another meta-analysis of 44 trials, tumor shrinkage was related to the choice of the somatostatin analog. Octreotide LAR appeared to be more potent than lanreotide SR, with an odds ratio of 9.4 (Freda et al 2005). Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal suggest that some well-responsive patients might be cured, but long-term follow up is clearly needed (Ronchi et al 2008).

Quality of life
QoL remains impaired in acromegaly even after successful pituitary surgery due to persisting joint-related complaints.
Predictors of clinical response
A priori conditions for a favorable clinical response to somatostatin analog therapy are the density and distribution of SSTR2a receptors in the adenoma (Lamberts et al 1996). It is controversial whether a single acute octreotide test can predict the clinical response during long-term treatment. In this respect 3 studies reported positive results (Biermasz et al 2005b; Gilbert et al 2005; Karavitaki et al 2005), whereas 3 others concluded that the test was not useful (Colao et al 1996; de Herder et al 2005; Prokajac et al 2005). The absolute height of pretreatment GH levels is obviously another important factor for the efficacy of treatment, and indeed several studies have demonstrated that tumor debulking procedures improved the clinical outcome of medical therapy (Colao et al 2006b; Karavitaki et al 2007).

Primary pharmacologic treatment
Patients with a high chance of curative surgery should be offered this treatment. However, primary medical treatment should be considered in patients with a high surgical risk, patients with large invasive tumors and obviously in those who refuse surgery. Dose escalation with short-acting octreotide resulted in a better outcome in patients treated with octreotide as primary medication than those who received this drug as adjuvant medication after surgery (Newman et al 1995). Given as primary treatment, octreotide LAR controlled GH secretion in 57%, IGF-I in 45%, and caused tumor reduction of more than 50% in 44% out of 99 patients (Colao et al 2006a). This group and Cozzi and colleagues also found that dose escalating resulted in an even better outcome (Cozzi et al 2003; Colao et al 2007). Limitations of these studies are that they are not randomized to primary surgery and that no data are available on long-term effects on survival.

Primary medical treatment may also be aimed at improvement of surgical outcome. Most of the studies addressing this issue had an open label design. Three studies reported beneficial effect on outcome (Barkan et al 1988; Colao et al 1997; Stevenaert and Beckers 1996), whereas three others did not (Biermasz et al 1999; Kristof et al 1999; Abe and Lüdecke 2001). Therefore, a conclusive statement cannot be made on this issue.

Failures of medical therapy
As outlined above, somatostatin analog treatment will not control clinical symptoms and biochemical parameters in all acromegalic patients, and about half of them will still have raised IGF-I and/or GH levels. An increase in the injection frequency of lanreotide Autogel® to once every 2–3 weeks is generally not successful (Abrams et al 2007). Another, less expensive approach is to combine treatment with dopaminergic agonists (Freda 2003; Cozzi et al 2004). More effective is combined treatment with pegvisomant as demonstrated by a single center open labeled study. Long-term efficacy of combined treatment was demonstrated in 32 patients who all normalized IGF-I with pegvisomant in a dose of 40–160 mg given once weekly (24 patients) or twice weekly (Neggers et al 2007). Two large multicenter studies are respectively ongoing and complete, in which weekly administered pegvisomant is combined with lanreotide Autogel® in patients not controlled during treatment with 120 mg lanreotide Autogel® (ClinicalTrials.gov, NCT 00383708) and daily pegvisomant injections with octreotide LAR (ClinicalTrials.gov, NCT 0068029). Preliminary results of the latter study suggest equal efficacy in the two randomized parallel treatment groups towards serum IGF-I normalization, but with a higher incidence of side effects in the combined treatment group (Harris et al 2007). Considering the number of patients included, these studies will most likely answer questions about the efficacy of combined somatostatin analog and GH-receptor blockage in the treatment of acromegaly. However, both studies did not exclude previous surgery or radiation therapy, so that any conclusions drawn from these studies may not be applicable to primary medical treatment.

Due the favorable receptor binding profile, SOM230 (pasireotide) is likely to be a powerful somatostatin analog, which might be used in therapy-resistant cases to the registered somatostatin analogs (van der Hoek et al 2005; Ben-Shlomo and Melmed 2007). Clinical Phase II studies
in acromegaly are now being carried out in the US with both the short-acting form as well as the slow-release formulation (ClinTrial.gov NCT000088582, NCT00171730, and NCT00600886). Other somatostatin agonists currently developed were recently reviewed (Roelfsema et al 2006). Potential interesting drugs are chimeric somatostatin analogs. This class of drugs combines dopamine and somatostatin structural elements and retains affinity for specific somatostatin and dopamine receptor subtypes. These new drugs can not only suppress GH (and other pituitary hormones) better than currently clinically used drugs, but may also have much stronger antiproliferative actions, at least in vitro (Ferone et al 2007; Zatelli et al 2007).

Summary and future perspectives
Lanreotide Autogel® is an exceptional pharmaceutical achievement, based on the unique property of self-aggregation of lanreotide. The formulation is delivered in prefilled syringes and can be easily injected without medical supervision by the patient or partner after proper training (Bevan et al 2008), whereas octreotide LAR requires qualified personnel for administration.

Lanreotide SR 30 mg/7–14 days can control serum GH in 59% and IGF-I concentrations in 49% of patients, while the results of the 60 mg formulation/4 weeks are 60% and 58%, respectively. Lanreotide Autogel® controls GH in 58% and IGF-I in 48% of patients. Compared with octreotide LAR the efficacy of lanreotide SR is less, although the differences are not large (Freda et al 2005). No large scale data are available for lanreotide Autogel®, a latecomer in this therapeutic field, for making a reasonable comparison with octreotide LAR.

The present formulations of somatostatin analogs can be classified as a second generation of effective GH-suppressive drugs, but these agents are clearly not adequate for all patients, depending on tumor somatostatin receptor status. New somatostatin analogs include SOM230, which is currently being used in several trials in the US, and the potentially very powerful chimeric drugs developed by Ipsen SA. The latter drugs, if successful in phase II–IV studies, will probably take another 5–10 years before becoming available for clinical use by endocrinologists. At present patients not controlled by somatostatin analogs should be treated with adjuvant pegvisomant, either as daily injections, as recommended by Pfizer, or as once-weekly or 2-weekly injections in a titrated dose, which data in the literature have suggested as sufficient (Feenstra et al 2005; Jørgensen et al 2005; Harris et al 2007; Neggers et al 2007). It is to be expected that other GH receptor blocking agents will become available in the future, which might not have the potential drawbacks of pegvisomant (Roelfsema et al 2006).

Disclosures
The authors have no conflict of interest and have received no payment in the preparation of this manuscript.

References
Abe T, Lüdecke DK. 2001. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol, 145:137–45.
Abras P, Alexopoulos O, Abs R, et al. 2007. Optimization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol, 157:571–7.
Abs R, Verhelst J, Maier D, et al. 1998. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab, 83:374–8.
Ahmed S, Elsheikh M, Stratton IM, et al. 1999. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf), 50:561–7.
Alexander L, Appleton D, Hall R, et al. 1980. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf), 12:71–9.
Alexopoulos O, Abrams P, Verhelst J, et al. 2004. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol, 151:317–24.
al-Maskari M, Gebbie J, Kendall-Taylor P. 1996. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf), 45:415–21.
Amato G, Mazzetti G, Rotondi M, et al. 2002. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf), 56:65–71.
Ambrosio MR, Franceschetti P, Bondanelli M, et al. 2002. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism, 51:387–93.
Andries M, Glintborg D, Kvistborg A, et al. 2008. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf), 68:473–80.
Antonijoan RM, Barbanoj MJ, Cordero JA, et al. 2004. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol, 56:471–6.
Ashwell SG, Bevan JS, Edwards OM, et al. 2004. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol, 150:473–80.
Astruc B, Marbach P, Bouterfa H, et al. 2005. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol, 45:836–44.
Attanasio R, Baldelli R, Pivonello R, et al. 2003b. Lanreotide 60 mg: a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab, 88:5258–65.
Attanasio R, Epaminonda P, Motti E, et al. 2003a. Gamma-knife radiotherapy, but not serum insulin-like growth factor I concentrations predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab, 89:1613–17.
Baldelli R, Battista C, Leonetti F, et al. 2003. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf), 59:492–9.
Baldelli R, Colao A, Razzore P, et al. 2000. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab, 85:4099–103.
Colao A, Marzullo P, Ferone D, et al. 1999. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest, 22:40–7.

Colao A, Pivonello R, Aurienma RS, et al. 2006a. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab, 91:212–18.

Colao A, Pivonello R, Aurienma RS, et al. 2007. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol, 157:579–87.

Cozzi R, Attanasio R, Montini M, et al. 2003. Four-year treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results by ROC analysis. J Clin Endocrinol Metab, 88:3090–8.

Cozzi R, Attanasio R, Lodrini S, et al. 2004. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf), 61:209–15.

Cozzi R, Barausse M, Ashnagh D, et al. 2001. Failure of radiotherapy in acromegaly. Eur J Endocrinol, 145:717–26.

Cozzi R, Barausse M, Sberna M, et al. 2000. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary, 3:231–8.

Cozzi R, Dallabonzana D, Attanasio R, et al. 1999. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol, 141:267–71.

Danila DC, Haidar JN, Zhang X, et al. 2001. Somatostatin receptor-specific agonists: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab, 86:2976–81.

De P, Rees DA, Davies N, et al. 2003. Transphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab, 88:3567–72.

De Herder WW, Taal HR, Uitterlinden P, et al. 2005. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin-LAR in acromegaly. Eur J Endocrinol, 153:67–71.

Dekkers OM, Biermasz NR, Pereira AM, et al. 2008. Mortality in acromegaly: a meta-analysis. J Clin Endocrinol Metab, 93:61–7.

Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wess JAH. 1992. Gallstones during octreotide therapy. Metabolism, 41(Suppl 2):22–33.

Epaminonda R, Porretti S, Cappiello V, et al. 2001. Efficacy of radiotherapy in normalizing serum IGF-I, acid labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol (Oxf), 55:183–9.

Ezzat S, Forster MJ, Berchtold P, et al. 1994. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore), 73:233–40.

Fahlbuch R, Keller B, Ganslandt O, et al. 2005. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol, 153:239–48.

Feenstra J, de Herder WW, ten Have SMTH, et al. 2005. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 365:63011–15.

Ferone D, Saveanu A, Culler MD, et al. 2007. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol, 156:S23–S8.

Fiorio T, Thellung S, Corsaro A, et al. 2003. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf), 59:115–28.

Foss MC, Saad MJ, Paccola GM, et al. 1991. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab, 72:1048–53.

Fougnier SL, Borot OC, Berg JP, et al. 2008. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf), 68:458–65.

Freda PU. 2003. How effective are current therapies for acromegaly? Growth Horm IGF Res, 13(Suppl 1):S144–S51.

Freda PU, Katznelson L, van der Lely AJ, et al. 2005. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab, 90:4465–73.

Freda PU, Wardlaw SL, Post KD, et al. 1998. Long-term endocrinological follow-up evaluation in 115 patients who underwent transphenoidal surgery for acromegaly. J Neurosurg, 89:353–8.

Gilbert JA, Miell JP, Chambers, et al. 2005. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxf), 62:742–7.

Giusti M, Ciccarelli E, Dallabonzana D, et al. 1997. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Endocrinol, 27:277–84.

Giustina A, Barkan A, Casanueva FF, et al. 2000. Consensus criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab, 85:526–9.

Greenman Y, Tordjman K, Kisch E, et al. 1995. Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J Clin Endocrinol Metab, 80:1577–83.

Guill S, Keles H, Delibasi T, et al. 2004. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol, 150:465–71.

Gupt B, Bidlingmaier M, Kretschmar K, et al. 2005. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes, 113:139–44.

Hansen I, Isilakian E, Beaufreire B, et al. 1986. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol, 250: E269–E73.

Harris PE, D’Souza G, Good AJ, et al. 2007. Treatmet ent with pegvisomant alone compared to combination therapy with pegvisomant/octreotide LAR in acromegaly. Abstract OR 53–3. The Endocrine Society Annual Meeting, Toronto, Ontario, Canada, June 2–5, 2007.

Heron I, Thomas F, Dero M, et al. 1993. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab, 76:721–7.

Ho KY, Weisberger AJ. 1994. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxf), 41:75–83.

Hofland LJ, Lamberts SWJ. 2003. The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance. Endocr Rev, 24:28–47.

Holdaway IM. 2007. Excess mortality in acromegaly. Horm Res, (Suppl 5):166–72.

Holdaway IM, Rajasooarya RC, Gamble GD. 2004. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab, 89:667–74.

Hradske J, Krai J, Janota T, et al. 1999. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol, 83:1306–9.

Hua SC, Yan YH, Chang TC. 2006. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol, 155:831–7.

Jaffe CA, Barkan AL. 1992. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am, 21:713–35.

Jenkins PJ, Besser M. 2001. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab, 86:2935–41.

Johnson MR, Chowdrey HS, Thomas F, et al. 1994. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol, 130:229–34.

Jørgensen JOL, Feldt-Rasmussen U, Frystyk J, et al. 2005. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab, 90:5627–31.

Kaltas GA, Isidori AM, Florakis D, et al. 2001. Predictors of outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab, 86:1645–52.
Karavitaki N, Butsana I, Radian S, et al. 2005. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. *Clin Endocrinol (Oxf)*, 62:282–8.

Karavitaki N, Turner HE, Adams CB, et al. 2007. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. *Clin Endocrinol (Oxf)*, doi: 10.1111/j.1365-2265.2007.03139.x.

Kasayama S, Otsuki M, Tagaki M, et al. 2000. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. *Clin Endocrinol (Oxf)*, 52:549–55.

Kauppinen-Makelin R, Sane T, Reunanen A, et al. 2005. A nationwide survey of mortality in acromegaly. *J Clin Endocrinol Metab*, 90:4081–6.

Kendall-Taylor P, Miller M, Ghebrie J, et al. 2000. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. *Pituitary*, 3:61–5.

Krantz S, Goddard I, Saveun A, et al. 2004. Novel modalities of somatostatin actions. *Eur J Endocrinol*, 151:643–55.

Kreutzer J, Vance ML, Lopes MB, et al. 2001. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. *J Clin Endocrinol Metab*, 86:4072–7.

Koop BL, Harris AG, Ezzat S. 1994. Effect of octreotide on glucose tolerance in acromegaly. *Eur J Endocrinol*, 130:581–6.

Krisof RA, Stoffel-Wagner B, Klingmuller D, et al. 1999. Does octreotide treatment improve the surgical results of macroadenomas in acromegaly? A randomized study. *Acta Neurochirurgica*, 141:399–405.

Kuhn JM, Basen C, Mollard M, et al. 1992. Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. *Eur J Clin Invest*, 22:793–7.

Kuhn JM, Legrand A, Ruiz JM, et al. 1994. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. *Br J Clin Pharmacol*, 38:213–19.

Lamberts SW, Van der Lely AJ, De Herder WW, et al. 1996. Octreotide. *Clin Pharmacol*, 52:549–55.

Landolt AM, Haller D, Lomax N, et al. 1998. Stereotactic radiosurgery for GH-secreting pituitary adenomas: an outcome study using current criteria of biochemical cure. *Eur J Endocrinol*, 138:503–9.

Lambert SW, Van der Lely AJ, De Herder WW, et al. 1996. Octreotide. *Clin Pharmacol*, 52:549–55.

Le Roith D, Bondy C, Yakar S, et al. 2001. The somatomedin hypothesis. *Eur J Clin Invest*, 31:602–7.

Loeper S, Ezzat S. 2008. Acromegaly: Re-thinking the cancer risk. *Rev Endocr Metab Disord*, 9:41–58.

Long H, Beauregard H, Somma M, et al. 1996. Surgical outcome after repeated transsphenoidal surgery in acromegaly. *J Neurosurg*, 85:239–47.

Lucas T, Astorga R, Catala M, et al. 2003. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. *Clin Endocrinol (Oxf)*, 58:471–81.

Lucas T, Astorga R, Spanish-Portuguese Multicentre Autogel Study Group. 2005. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microspheres 30 mg: a phase III trial. *Clin Endocrinol (Oxf)*, 65:320–6.

Lüdecke DK, Abe T. 2006. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1000 operations. *Neuroendocrinology*, 83:230–9.

Mahmoud-Ahmed AS, Suh JH, Mayberg MR. 2001. Gamma knife radiosurgery in the management of patients with acromegaly: a review. *Pituitary*, 4:223–30.

Maison P, Tropcano A-I, Macquin-Mavier I, et al. 2007. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. *J Clin Endocrinol Metab*, 92:1743–7.

Marcou Y, Plowman PN. 2000. Stereotactic radiosurgery for pituitary adenomas. *Trends Endocrinol Metab*, 11:132–7.

Marek J, Hana V, Krasek M, et al. 1994. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. *Eur J Endocrinol*, 131:20–26.
Ronchi CL, Boschetti M, Degli Uberti EC, et al. 2007. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 67:512–19.

Ronchi CL, Orsi E, Giavoli C, et al. 2003. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest, 26:533–8.

Ronchi CL, Rizzo E, Lania AG, et al. 2008. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol. 158:19–25.

Rowles SV, Prieto L, Badia X, et al. 2005. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab. 90:3337–41.

Schade R, Andersohn F, Suisse S, et al. 2007. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med, 356:29–38.

Schloffer H. 1907. Erfolgreiche Operation eines Hypophysentumors auf nasalem Wege. Wien Klin Wochenschr, 20:621–4.

Schreiber I, Buchfelder M, Droste M, et al. 2007. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol, 156:75–82.

Serri O, Brazeau P, Kachra Z, et al. 1992. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology, 130:1816–21.

Sheehan JP, Niranjan A, Sheehan JM, et al. 2005. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and the role in the neurosurgical treatment armamentarium. J Neurosurg, 102:678–91.

Shimon I, Cohen ZR, Ram Z, et al. 2001. Transphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery, 48:1239–43.

Sjogren K, Liu JL, Blad K, et al. 1999. Liver-derived insulin-like growth factor I (IGF-I) is the principle source of IGF-I in blood but it is not required for postnatal body growth in mice. Proc Natl Acad Sci USA, 96:7088–92.

Sonino N, Scarpa E, Paoletta A, et al. 1999. Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychosom Med, 61:185–7.

Sonksen PH, Greenwood FC, Ellis JP, et al. 1967. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol Metab, 27:1418–30.

Steffin B, Gutt B, Bidlingmaier M, et al. 2006. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol, 155:73–8.

Stevenaert A, Beckers A. 1996. Presurgical octreotide treatment in acromegaly. Metabolism, 45(Suppl 1):72–4.

Sullivan M, Jenkins R, Ross R, et al. 1999. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest, 22:409–18.

Swaarlingen B, Barker FG, Katzenelson L, et al. 1998. Long-term mortality after transphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab, 83:3419–26.

Taboada GF, Luque RM, Neto LV, et al. 2008. Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol, 158:295–303.

Thalassinos NC, Tsagarakis S, Ioannides G, et al. 1998. Megavoltage pituitary irradiation lowers, but seldom leads to safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol, 138:160–3.

Thomale UW, Stover JF, Unterberg AW. 2005. The use of neuronavigation in transnasal transphenoidal pituitary surgery. Zentralbl Neurochir, 66:126–32.

Trainer PJ, Drake WM, Katzenelson L, et al. 2000. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med, 342:1171–7.

Turner HE, Vadivale A, Keenan J, Wass JA. 1999. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf), 51:275–280.

Valéry C, Pатenostre M, Robert B, et al. 2003. Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Natl Acad Sci USA, 100:10258–62.

Valéry C, Pouget E, Pandit A, et al. 2008. Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach. Biophys J, 94:1782–95.

Van den Berg G, Frolich M, Veldhuis JD, et al. 1994. Growth hormone secretion in recently operated acromegalic patients. J Clin Endocrinol Metab, 79:1706–15.

Van den Berg G, Pincus SM, Frolich M, et al. 1998. Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery. Eur J Endocrinol, 138:164–9.

Van der Hock J, Lamberts SW, Hofland LJ. 2004. The role of somatostatin analogs in Cushing’s disease. Pituitary, 7:257–64.

Van der Hock J, van der Lely AJ, Feelders RA, et al. 2005. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf), 63:176–84.

Van der Lely AJ, Hutson RK, Trainer PJ, et al. 2001. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358:1754–9.

Van Thiel SW, Bax JJ, Biermasz NR, et al. 2005. Persistent diastolic valve regurgitation after transsphenoidal surgery and adjunctive therapy for acromegaly. Clin Endocrinol (Oxf), 153:231–8.

Van Thiel SW, Romijn JA, Biermasz NR, et al. 2004. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol, 150:489–95.

Verhelst JA, Pedroncelli AM, Abs R, et al. 2000. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol, 143:577–84.

Wasco R, Jankowska A, Kotwicka M, et al. 2003. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas. Neuro Endocrinol Lett, 24:334–8.

Wass JA. 2003. Radiotherapy in acromegaly: a protagonist’s viewpoint. Clin Endocrinol (Oxy), 58:128–31.

Wass JA, Cudworth AG, Bottazzo GF, et al. 1980. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxy), 12:53–59.

Wright AD, Hill DM, Lowy C, et al. 1970. Mortality in acromegaly. Q J Med, 39:1–16.

Zatelli MC, Ambrosio MR, Bondanelli M, et al. 2007. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur J Endocrinol, 156:S29–S35.
